©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Ophthalmol. Aug 12, 2015; 5(3): 125-132
Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.125
Published online Aug 12, 2015. doi: 10.5318/wjo.v5.i3.125
Intravitreal drug administration for treatment of noninfectious uveitis
Alper Yazici, Department of Ophthalmology, Balıkesir University School of Medicine, 10145 Balıkesir, Turkey
Pinar C Ozdal, Department of Ophthalmology, Ulucanlar Eye Training and Research Hospital, 06240 Ankara, Turkey
Author contributions: Both authors contributed to this manuscript.
Conflict-of-interest statement: None of the authors have conflict of interest.
Correspondence to: Alper Yazici, MD, Assistant Professor, Department of Ophthalmology, Balıkesir University School of Medicine, 17. Km Bigadic Road, Cagis Campus Balikesir University Hospital, 10145 Balikesir, Turkey. lpryzc@yahoo.com
Telephone: +90-50-53937586 Fax: +90-21-66121023
Received: February 25, 2015
Peer-review started: February 26, 2015
First decision: April 10, 2015
Revised: May 26, 2015
Accepted: June 15, 2015
Article in press: June 16, 2015
Published online: August 12, 2015
Processing time: 172 Days and 15.8 Hours
Peer-review started: February 26, 2015
First decision: April 10, 2015
Revised: May 26, 2015
Accepted: June 15, 2015
Article in press: June 16, 2015
Published online: August 12, 2015
Processing time: 172 Days and 15.8 Hours
Core Tip
Core tip: The limitations related to the systemic use of treatment options in noninfectious posterior uveitis yielded intravitreal route. The hallmark of intravitreal treatment triamcinolone acetonide has a short half-life with a high rate of intraocular complications, and this led to the development of implants as a treatment option with various agents in the market still under investigation. In this review, we try to summarize the intravitreal therapeutic options that are being used in noninfectious uveitis.